- Home
- HOOK vs IBO Comparison
HOOK vs IBO Comparison
Compare HOOK & IBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOOK
- IBO
- Stock Information
- Founded
- HOOK 2011
- IBO 2018
- Country
- HOOK United States
- IBO United States
- Employees
- HOOK N/A
- IBO N/A
- Industry
- HOOK Biotechnology: Pharmaceutical Preparations
- IBO
- Sector
- HOOK Health Care
- IBO
- Exchange
- HOOK Nasdaq
- IBO NYSE
- Market Cap
- HOOK 24.5M
- IBO 22.1M
- IPO Year
- HOOK 2019
- IBO 2024
- Fundamental
- Price
- HOOK $1.78
- IBO $2.12
- Analyst Decision
- HOOK Buy
- IBO
- Analyst Count
- HOOK 4
- IBO 0
- Target Price
- HOOK $10.67
- IBO N/A
- AVG Volume (30 Days)
- HOOK 44.7K
- IBO 23.0K
- Earning Date
- HOOK 03-21-2025
- IBO 03-04-2025
- Dividend Yield
- HOOK N/A
- IBO N/A
- EPS Growth
- HOOK N/A
- IBO N/A
- EPS
- HOOK N/A
- IBO 0.01
- Revenue
- HOOK $49,999,000.00
- IBO N/A
- Revenue This Year
- HOOK $148.80
- IBO N/A
- Revenue Next Year
- HOOK N/A
- IBO N/A
- P/E Ratio
- HOOK N/A
- IBO $175.47
- Revenue Growth
- HOOK 143.30
- IBO N/A
- 52 Week Low
- HOOK $1.65
- IBO $1.16
- 52 Week High
- HOOK $10.50
- IBO $3.25
- Technical
- Relative Strength Index (RSI)
- HOOK 41.23
- IBO N/A
- Support Level
- HOOK $1.77
- IBO N/A
- Resistance Level
- HOOK $1.96
- IBO N/A
- Average True Range (ATR)
- HOOK 0.12
- IBO 0.00
- MACD
- HOOK 0.00
- IBO 0.00
- Stochastic Oscillator
- HOOK 41.40
- IBO 0.00
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies.
About IBO IMPACT BIOMEDICAL INC
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The Company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza.